| Cleveland BioLabs is a biopharmaceutical company. Co.'s product candidate, Entolimod is a Toll-like receptor 5 (TLR5) agonist, which Co. is developing as a medical radiation countermeasure for reducing the risk of death following exposure to potentially lethal irradiation Acute Radiation Syndrome. Co.'s other product candidate, Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, a secretory non-glycosylated version of entolimod Co. is also developing through its subsidiary, Panacela Labs, Inc. Two randomized, placebo-controlled, dose-ranging studies of Mobilan in men with prostate cancer are ongoing in the Russian Federation. We show 28 historical shares outstanding datapoints in our CBLI shares outstanding history coverage, used to compute CBLI market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CBLI market cap history over the course of time is important for investors
interested in comparing CBLI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CBLI versus a peer is one thing; comparing
CBLI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CBLI can fluctuate over the course of history.
With this page we aim to empower investors researching CBLI by allowing them to research the CBLI market cap history.